Alan Roemer, MBA, MPH is an entrepreneurial life sciences executive and board member who has launched three multi-billion-dollar biotechnology companies resulting in 9 new drug approvals, raised approximately $2 billion in private and public capital, consummated five IPOs, and executed numerous business development transactions.
Mr. Roemer is the Chairman of the Board of Directors of IN8bio (Nasdaq:INAB); a Trustee and Treasurer of the Helene Fuld College of Nursing; a Strategic Partner of Forty51 Ventures; a Senior Advisor of Biolojic Design; an Advisor and SAB Member of SEED Therapeutics; and a Management Committee Member of DC Brau Brewing. He previously served as Chairman of the Board of Directors of UTILITY Therapeutics (acquired by Alembic Pharmaceuticals); a Director and Chair of the Audit, Compensation and Finance Committees of Bit.Bio; a Director and Audit Committee Chair of NexImmune (Nasdaq:NEXI); a Director of Envisagenics; and a Director of SomPharmaceuticals (acquired by Amryt Pharma (Nasdaq:AMYT), subsequently acquired by Chiesi Farmaceutici).
Mr. Roemer was a Founding Leadership Team member of Roivant Sciences (Nasdaq:ROIV), and he served in various senior management roles responsible for finance, operations, and corporate development from Roivant’s inception in May 2014 to August 2019. In 2015, he simultaneously served as Principal Financial and Accounting Officer of Axovant Sciences Ltd. (Nasdaq:AXON) and Chief Financial Officer and a Founding Leadership Team member of its wholly-owned subsidiary, Axovant Sciences, Inc. Prior to launching Roivant and Axovant, Mr. Roemer was a Managing Director of the Trout Group, and he previously served as Chief Financial Officer & Treasurer of Zelos Therapeutics. From 1999 to 2008, Mr. Roemer was a Vice President of Pharmasset (Nasdaq:VRUS; acquired by Gilead (Nasdaq:GILD). He wrote the formal business plan for the scientific founder and was Pharmasset’s first full-time leadership team member, responsible for the early-stage operational and administrative infrastructure, business development activities, and fundraising transactions.
Mr. Roemer received a BSBA from Georgetown University and MBA and MPH degrees from Emory University’s Goizueta Business School and Rollins School of Public Health.